Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Trametinib and dabrafenib combination therapy against metastatic melanoma

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.12
Views: 4017

Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia

Dr Georgina Long talks with ecancer at the 2012 ESMO meeting about a highly successful phase II trial that tested a BRAF and MEK inhibitor combination therapy against metastatic melanoma.


The majority of patients quickly develop resistance to BRAF inhibitors so combination therapy was introduced to improve response and progression free survival.


Results from the study showed 61 percent of patients, in the combination arm, to have reduction in risk, resistance and death, with prolonged response averaging 9.4 months.


The most significant statistic from the study was an increase from 33 percent of patients reaching the 12-month survival mark two years ago to 79 percent of patients reaching that mark today. Side effects from the treatment, such as manageable toxicities, are explained through the biology of the treatment. 


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation